137 related articles for article (PubMed ID: 17110455)
1. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance.
Loebstein R; Dvoskin I; Halkin H; Vecsler M; Lubetsky A; Rechavi G; Amariglio N; Cohen Y; Ken-Dror G; Almog S; Gak E
Blood; 2007 Mar; 109(6):2477-80. PubMed ID: 17110455
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic.
Shuen AY; Wong BY; Fu L; Selby R; Cole DE
Clin Biochem; 2012 Apr; 45(6):397-401. PubMed ID: 22266406
[TBL] [Abstract][Full Text] [Related]
3. The VKORC1 Asp36Tyr variant and VKORC1 haplotype diversity in Ashkenazi and Ethiopian populations.
Sominsky S; Korostishevsky M; Kurnik D; Aklillu E; Cohen Y; Ken-Dror G; Loebstein R; Halkin H; Gak E
J Appl Genet; 2014 May; 55(2):163-71. PubMed ID: 24425227
[TBL] [Abstract][Full Text] [Related]
4. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
[TBL] [Abstract][Full Text] [Related]
5. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
Miao L; Yang J; Huang C; Shen Z
Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
[TBL] [Abstract][Full Text] [Related]
6. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Limdi NA; Beasley TM; Crowley MR; Goldstein JA; Rieder MJ; Flockhart DA; Arnett DK; Acton RT; Liu N
Pharmacogenomics; 2008 Oct; 9(10):1445-58. PubMed ID: 18855533
[TBL] [Abstract][Full Text] [Related]
7. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
9. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
[TBL] [Abstract][Full Text] [Related]
10. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.
Vecsler M; Loebstein R; Almog S; Kurnik D; Goldman B; Halkin H; Gak E
Thromb Haemost; 2006 Feb; 95(2):205-11. PubMed ID: 16493479
[TBL] [Abstract][Full Text] [Related]
11. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population.
Efrati E; Elkin H; Sprecher E; Krivoy N
Curr Drug Saf; 2010 Jul; 5(3):190-3. PubMed ID: 20210733
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin.
Miyagata Y; Nakai K; Sugiyama Y
Int Heart J; 2011; 52(1):44-9. PubMed ID: 21321468
[TBL] [Abstract][Full Text] [Related]
13. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
14. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals.
Aklillu E; Leong C; Loebstein R; Halkin H; Gak E
Blood; 2008 Apr; 111(7):3903-4. PubMed ID: 18362220
[No Abstract] [Full Text] [Related]
15. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation.
Geisen C; Watzka M; Sittinger K; Steffens M; Daugela L; Seifried E; Müller CR; Wienker TF; Oldenburg J
Thromb Haemost; 2005 Oct; 94(4):773-9. PubMed ID: 16270629
[TBL] [Abstract][Full Text] [Related]
16. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
[TBL] [Abstract][Full Text] [Related]
18. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
[TBL] [Abstract][Full Text] [Related]
19. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records.
Osman A; Enström C; Arbring K; Söderkvist P; Lindahl TL
J Thromb Haemost; 2006 Aug; 4(8):1723-9. PubMed ID: 16879214
[TBL] [Abstract][Full Text] [Related]
20. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]